Vertex Pharmaceuticals Incorporated (VRTX) — Form SCHEDULE 13G/A: Ownership over 5% (passive) (amendment)

Capital Research Global Investors filed an amended Schedule 13G reporting a passive stake in Vertex Pharmaceuticals Incorporated Common Stock. As of 09/30/2026, the filer beneficially owns 17,821,661 shares, representing 7.0% of the class.